However, by performing flowcytometry, we are the first to show that knocking down CCL22 significantly decreased the MFI of CD206 in TAMs of cervical cancer compared with the control group, which indicated that CCL22 could polarize TAMs to M2a macrophages. The gene discussed is CCL22; the disease is cervical carcinoma.